Bristol-Myers Squibb Co.

Total sales for Bristol-Myers Squibb’s Opdivo increased 34%, from $1.1 billion in 1Q17 to $1.5 billion in 1Q18.

Major developments As discussed previously in this series, Johnson & Johnson’s (JNJ) 3Q16 performance was positive across all of its segments. However, the Consumer segment reported a decline in revenue, as the negative impact of foreign exchange more than offset operational growth. There were several major developments for JNJ during 3Q16. Pharmaceuticals segment In 3Q16, the […]

Of the 23 analysts covering Bristol-Myers Squibb (BMY) in August 2017, six analysts recommended a “strong buy,” and four analysts recommended a “buy.” Ten analysts recommended a “hold,” and three analysts recommended a “sell.”

Merck provided revenue guidance of $39.7 billion–$40.2 billion in 2016. It expects negative foreign exchange fluctuations to reduce its fiscal 2016 revenue.

With manufacturing slowing, a reading of the Non-Manufacturing Index at an above-neutral level (56.9) may provide some relief to the US economy, which is highly dependent on the service sector for its economic growth.

Headquartered in New Jersey, Johnson & Johnson (JNJ) is one of the largest pharmaceutical companies, with its products sold in over 200 countries worldwide. This series will look at how it has performed since its 2Q17 earnings announcement.

For 2016, Merck & Co. (MRK) reported revenue close to $39.8 billion, a year-over-year (or YoY) rise of ~1%. New product launches have played major roles in boosting Merck’s 2016 revenue.

Of 28 analysts covering BMY’s stock, 42.3% gave it a “buy” recommendation, while 50.0% gave it a “hold” recommendation. Only 7.7% rated it as a “sell.”

According to unaudited financial results published by Celgene (CELG) on January 9, 2017, Revlimid sales for 2016 are about $7.0 billion, a YoY rise of about 20.0%.

For 3Q17, analysts estimate that Eli Lilly will post EPS of $1.03 on revenues of $5.5 billion.

Allergan’s US medical aesthetics segment includes facial aesthetics, medical dermatology products, and a wide range of silicone and saline breast implants.

BMY has four key oncology products, including Erbitux, Opdivo, Sprycel, and Yervoy. Two of these contributed more than $1 billion in 2014.

On October 24, 2016, the FDA approved Merck & Co’s (MRK) Keytruda as a second-line therapy for patients suffering from non-small cell lung cancer (or NSCLC).

AstraZeneca’s (AZN) CVMD (Cardiovascular and Metabolic Disease) segment contributed nearly 32.4% of total company revenues in 3Q16.

the U.S. Food and Drug Administration accepted the filing of a supplemental Biologics License Application for Bristol-Myers Squibb’s Opdivo.

Bristol-Myers Squibb estimates that its revenues will be between $15.5 billion and $15.9 billion, which is nearly flat as compared to 2014 revenues of $15.9 billion.

In addition to the US market, Merck’s (MRK) Keytruda has been approved in more than 50 international markets for metastatic melanoma.

After the approval of the drug as a therapy for newly diagnosed multiple myeloma, Celgene’s Revlimid has witnessed rapid growth in market share worldwide.

Of the three analysts tracking Novartis in November 2017, one recommends a “strong buy,” while two recommend a “hold.”

Xtandi is the major factor behind Pfizer’s (PFE) interest in Medivation (MDVN). The drug, along with MDVN’s pipeline molecules, should strengthen Pfizer’s (PFE) oncology franchise.

Viekira Pak managed to earn revenues worth about $414 million in 1Q16. The drug’s sales in the US market, however, fell YoY (year-over-year) by about 9.3% and reached $125 million in 1Q16.

On July 11, Opko Health (OPK) stock closed at $6.01, which represents 126% growth from its 52-week low of $2.66 in March.

Biogen (BIIB) has entered into a licensing agreement with Bristol-Myers Squibb (BMY) for exclusive global rights for the development and commercialization of BMS-986168.

Sales for Bristol-Myers Squibb’s (BMY) neuroscience segment declined over 80% in 2Q15, while the immunoscience segment’s sales improved ~15% in 2Q15 as compared to 2Q14.

Sales from Bristol-Myers Squibb’s Neuroscience segment declined by 94% in 1Q16. Sales from the Immunoscience segment improved by ~18.7% in 1Q16 over 1Q15.

AbbVie (ABBV) plans to complete its Phase 3 registrational program for investigational next-generation Hepatitis C virus (or HCV) therapy by 2016.

Wall Street analysts estimate Bristol-Myers Squibb’s top line to rise 6.5% to ~$5.2 billion in 1Q18.

Johnson & Johnson (JNJ) reported revenues of $20.0 billion during 1Q18, 12.6% growth as compared to revenues of $17.8 billion during 1Q17.

During the last quarter, the oncology segment’s contribution to AstraZeneca (AZN) increased to over 15%. AZN’s key products for oncology are Zoladex, Faslodex, Iressa, and the new drug Tagrisso.

Merck’s (MRK) Keytruda (pembrolizumab) is approved to treat various forms of cancer.

Bristol-Myers Squibb’s (BMY) neuroscience segment sales fell over 37% in 3Q16, while the immunoscience segment sales rose ~18% in 3Q16 as compared to 3Q15.

During 2016, Pfizer (PFE) succeeded in expanding its label for Ibrance, its breast cancer treatment.

Due to the decelerating revenue growth over all segments, Johnson & Johnson (JNJ) reported a decrease in its top line by ~8.8% in its 2Q15 earnings release on July 14, 2015.

Bristol-Myers Squibb’s (BMY) other segments include the Neuroscience segment, the Cardiovascular segment, and the Immuno-Science segment.

Roche Holding (RHHBY) generated ~78% of its group sales from the pharmaceuticals division.

On December 9, 2016, the FDA accepted for review its first-ever biologics license application (or BLA) submitted by AstraZeneca (AZN).

To ensure long-term relevance as well as quick adaptability to changing market needs, Novartis (NVS) is focusing on five major initiatives in 2017.

On November 10, 2016, the FDA approved Opdivo as a treatment option for patients suffering with recurring or metastatic squamous cell carcinoma of the head and neck (or SCCHN).

Exelixis (EXEL) plans to explore Cabometyx in combination with immune checkpoint inhibitors such as atezolizumab, ipilimumab, and nivolumab.

BioMarin Pharmaceutical (BMRN) reported its 3Q16 earnings on October 27, 2016. Revenues were $279.9 million, which was lower than Wall Street analysts’ projections.

In addition to Humira, AbbVie also offers several virology drugs targeting diseases such as hepatitis C, HIV, and respiratory syncytial virus.

Johnson & Johnson reported growth across all three of its segments: the pharmaceutical segment, the consumer health segment, and the medical devices segment.

On December 23, 2015, Seattle Genetics and Bristol-Myers Squibb announced the initiation of Phase 1 and 2 clinical trials of ADCETRIS.

Since the launch of Sovaldi in late 2013, Gilead Sciences has managed to treat about 1,000,000 hepatitis C (or HCV) patients globally.

Wall Street analysts have projected AstraZeneca’s (AZN) 2017 net profit margins at about 12.2%, which is lower by 300 basis points on a YoY basis.

Approximately 85% of all lung cancers in the United States are non-small cell lung cancers, and 10% to 15% of these are EGFR mutation-positive.

Novartis’s Innovative Medicines segment, formerly referred to as the Pharmaceutical segment, consists of products for a variety of therapeutic areas.

Launched in Japan in 2Q16, AstraZeneca’s (AZN) 1Q17 revenues for Tagrisso approached $39 million in this major emerging market.

In July 2017, the FDA accepted Bristol-Myers Squibb’s supplemental New Drug Application (or sNDA) for expanding the indication of Sprycel.

The overall contribution of the Innovative Medicines segment is ~67% of Novartis’s total revenues.

The U.S. Food and Drug Administration (or FDA) granted breakthrough therapy designation to Merck’s (MRK) grazoprevir/elbasvir (100mg/50mg) combination therapy.

In 2Q17, Amgen’s (AMGN) Aranesp generated revenues of ~$535 million, which represented a 6% year-over-year rise.

Bristol-Myers Squibb beat Wall Street analysts’ estimates for earnings per share and revenues in 1Q18.

In this series, we’ll look at Pfizer’s main revenue drivers in 2017, and what could steer its performance in 2018.

As per Wall Street analysts estimates, Johnson & Johnson (JNJ) is expected to report adjusted EPS (earnings per share) of $2.07 in the second quarter of fiscal 2018.

Bristol-Myers Squibb’s (BMY) neuroscience segment’s sales declined by 63.0% in 2015 from 2014, while its immunoscience segment’s sales improved ~14.1%.

Roche’s big three contributors include MabThera/Rituxan, Herceptin, and Avastin, which accounted for 14.7%, 13.9% and 13.7% of revenues in fiscal 1Q16.

AbbVie (ABBV) expects to secure FDA (U.S. Food & Drug Administration) approval in the third-line plus small cell lung cancer (or SCLC) indication in 2018.

Alcon, NVS’s eye care segment, saw its 4Q16 revenues fall ~2% to ~$1.4 billion, including no change in sales but a -2% impact from foreign exchange.

Eli Lilly and Company’s (LLY) Human Pharmaceutical segment includes cardiovascular products such as Cialis, Effient, and other products.

In 2018, stock markets, especially in the pharmaceutical sector, have seen heightened volatility.

The PD-1 (programmed death-1)/PD-L1 (programmed death-ligand 1) class consists of Bristol-Myers Squibb’s Opdivo, Merck’s Keytruda, and Roche’s Tecentriq.

In June, Johnson & Johnson (JNJ) accepted a binding offer from Platinum Equity to acquire its LifeScan business for ~$2.1 billion.

AstraZeneca’s (AZN) oncology products include legacy oncology products as well as new oncology products.

AGN’s analysts estimate EPS of $4.72 on revenues of $4.27 billion for 4Q17, which would be 10.5% higher YoY (year-over-year).

Bristol-Myers Squibb (BMY) reported a growth of 9% in 1Q16. Analyst estimates forecast a high-single-digit growth to low-double-digit in revenues in 2016.

In the fourth quarter of 2019, Tesla was Renaissance Technologies’ second-largest holding. Renaissance is one of the largest hedge funds in the US.

At the end of the third quarter, Bristol-Myers Squibb, Celgene, Biogen, UnitedHealth, and Walmart (WMT) were Renaissance Technologies’ top five buys.

AbbVie (ABBV) is currently evaluating more than 20 investigational therapies targeting solid tumors. Seventeen of them are in Phase 1 trials.

AbbVie (ABBV) aims to position its investigational therapy Rova-T (rovalpituzumab tesirine) as a standard of care treatment for patients with SCLC (small cell lung cancer).

The S&P 500 Index, which is trading close to an all-time high, could be affected by the Fed’s tone in its upcoming meeting.

Is Bristol-Myers Squibb stock undervalued, and could it surge higher anytime soon? Find out why further upside is possible for BMY.

Seattle Genetics (SGEN) is focused on maximizing Adcetris’ market reach. Currently, the product is sold in 71 countries.

On August 26, Amgen (AMGN) announced the purchase of leading immunology drug Otezla from Celgene (CELG) for a cash consideration of $13.4 billion.

According to the company’s fourth-quarter earnings conference call, Novartis expects to complete the spin-off of its Alcon business in the second quarter of 2019.

Since fiscal 2018, Novartis (NVS) has been focused on transforming itself into a new focused medicines company.

Bristol-Myers Squibb will release its second-quarter earnings on Thursday. The revenues will likely rise 7.16% YoY to $6.11 billion in the second quarter.

In the latest update on the pending merger with Celgene (CELG), Bristol-Myers Squibb (BMY) proposed plans to divest Otezla—Celgene’s top-selling non-biologic psoriasis drug.

This year, Pfizer (PFE) stock has fallen 0.34% and Bristol-Myers Squibb (BMY) stock has fallen 6.48%. Both companies are focused on strengthening their position in the high-growth oncology and immunology markets. Let’s take a closer look at each.

Pfizer’s (PFE) commercialized JAK (Janus kinase) inhibitor, Xeljanz, is approved for treating rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.

Pfizer (PFE) has guided for fiscal 2019 adjusted costs of sales as a percentage of revenue of 20.8%–21.8%, and adjusted selling, informational, and administrative expenses of $13.5 billion–$14.5 billion.

Bristol-Myers Squibb (BMY) issued a press release announcing shareholder approval of its proposed acquisition of Celgene in April.

Bristol-Myers Squibb’s (BMY) acquisition of Celgene (CELG) is expected to make the combined company a top-five player in the I&I (immunology and inflammation) space.

Bristol-Myers Squibb’s (BMY) acquisition of Celgene (CELG) is expected to result in a dominant player in IO (immuno-oncology), solid tumors, and hematology segments.

Bristol-Myers Squibb (BMY) highlighted the possibility of six new-term product launches after the completion of the acquisition of Celgene (CELG).

Bristol-Myers Squibb (BMY) estimated the value of currently marketed products of the combined company after completion of the acquisition of Celgene (CELG) to be $55 billion.

Bristol-Myers Squibb has guided for more than $45 billion of free cash flow in the first three years after completion of the deal.

Starboard Value has decided to give up the proxy war to stop Bristol-Myers Squibb’s deal with Celgene.

On February 25, Roche Holdings (RHHBY) issued a press release announcing that it has entered a definitive agreement to acquire Spark Therapeutics (ONCE).

Of the 15 analysts covering Merck, six recommend a “strong buy,” seven recommend a “buy,” and two recommend a “hold.”

In fiscal 2018, Bristol-Myers Squibb (BMY) reported revenues of $22.56 billion—a rise of 8.59% YoY (year-over-year).

Bristol-Myers Squibb’s (BMY) acquisition of Celgene (CELG) will add the latter’s blockbuster multiple myeloma (or MM) drugs, Revlimid and Pomalyst, to the company’s portfolio.

According to Bristol-Myers Squibb’s (BMY) investor presentation, the company expects to create a leading oncology franchise across both solid tumor and hematologic malignancy segments.

According to Bristol-Myers Squibb’s (BMY) press release, the company expects the acquisition of Celgene (CELG) to result in annual cost synergies close to $2.5 billion.

The acquisition of Celgene (CELG) by Bristol-Myers Squibb (BMY) brings together both the company’s leading franchises.

Bristol-Myers Squibb has agreed to acquire Celgene in a cash and stock transaction valued at around $74.0 billion.

In the first nine months of this year, Pfizer’s (PFE) Xtandi alliance revenue grew ~21% YoY (year-over-year) to $510.0 million.

Pfizer’s net revenues were $39.7 billion in the first nine months of 2018—compared to $38.8 billion during the same period in 2017.

Pfizer’s (PFE) stock price opened at $36.23 on January 2 and reached $43.51 on November 16, which represents ~20.0% growth YTD.